Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612339 · ClinicalTrials.gov registry record · Phase 2
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00612339 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 41 participants.
The verdict
NCT00612339, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Primary objective- To determine efficacy of Avastin, 10 mg/kg every other week, in combination with standard 5-day temozolomide in terms of response rate. Secondary objective- To determine safety of Avastin \& Temozolomide in unresectable glioblastoma patients
Interventions
- DRUG Avastin and Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612339
The ClinicalTrials.gov registry entry for NCT00612339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avastin and Temozolomide is the first listed.
NCT00612339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612339 about?
NCT00612339 is a clinical study titled "Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas". Primary objective- To determine efficacy of Avastin, 10 mg/kg every other week, in combination with standard 5-day temozolomide in terms of response rate. Secondary objective- To determine safety of Avastin \& Temozolomide in unresectable glioblastoma patients
What is the current status of trial NCT00612339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-08. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00612339?
The interventions under investigation include: Avastin and Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00612339?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.